Diaceutics (DXRX): FY 2026 revenue growth guidance
This situation live
DXRX Diaceutics
15 Jan 2026 · 25% FY 2026 revenue growth guided · −3% until the next step
The Company expects to deliver 25% revenue growth in FY 2026
26 May 2026 · Reaffirmed as on track; Q1 up 15% constant currency · −13% until the next step
The success of the Company's strategy and strength of its order book and pipeline provide the Board with confidence that their targets for 2026 are on track
29 Jul 2026 · On track; H1 +22% cc, 91% visibility · +41% until the next step
Delivering on median consensus revenue estimates would see a 38:62 H1:H2 split of 2026 revenue, similar to and supportive of prior year seasonality (FY 2025: 38:62).
22 Sep 2026 · On track; visibility 107% of consensus at 31 August · +5% since
The Board remains confident in delivering against its 2026 expectations.
FY 2026 revenue growth guidance
On track; visibility 107% of consensus at 31 August
Next: conversion of pipeline into H2 revenue; FY26 outcome
Every step · 4
- 15 Jan 2026 25% FY 2026 revenue growth guided – The Company expects to deliver 25% revenue growth in FY 2026 ↗
- 26 May 2026 Reaffirmed as on track; Q1 up 15% constant currency – The success of the Company's strategy and strength of its order book and pipeline provide the Board with confidence that their targets for 2026 are on track ↗
- 29 Jul 2026 On track; H1 +22% cc, 91% visibility – Delivering on median consensus revenue estimates would see a 38:62 H1:H2 split of 2026 revenue, similar to and supportive of prior year seasonality (FY 2025: 38:62). ↗
- 22 Sep 2026 On track; visibility 107% of consensus at 31 August – The Board remains confident in delivering against its 2026 expectations. ↗
What is happening
Diaceutics: FY 2026 revenue growth guidance – On track; visibility 107% of consensus at 31 August. ['On track; visibility 107% of consensus at 31 August']
- Announced
- 15 Jan 2026 · 25% FY 2026 revenue growth guided
- Latest
- 22 Sep 2026 · On track; visibility 107% of consensus at 31 August
- What it changes
- Retention and recurring revenue improved again and visibility rose to 107% of consensus, but there is no guidance raise. Statutory EBITDA (-£655k) and loss before tax (-£4.0m) remain negative.
What comes next
conversion of pipeline into H2 revenue; FY26 outcome.
From the company's own announcements. Not investment advice.
Briefing Pro
New to Diaceutics? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the DXRX briefing →Also at Diaceutics 0 open
Insider conviction1 director buying – £16k in 1 buy · closed
Diaceutics – company page →